- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07946497
CAPN12 Gene Expression as a Molecular Discriminator
CAPN12 Gene Expression as a Molecular Discriminator Between Methotrexate Treated Chronic Plaque Psoriasis and Psoriatic Arthritis
Psoriasis is a chronic immune-mediated inflammatory disease with systemic manifestations. Psoriatic arthritis is an important extracutaneous manifestation that can lead to progressive joint damage and functional disability if not recognized early.
Methotrexate remains a commonly used systemic therapy in both chronic plaque psoriasis and psoriatic arthritis, mainly through anti-inflammatory and immunomodulatory effects.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Psoriasis is a chronic immune-mediated inflammatory disease with systemic manifestations. Psoriatic arthritis is an important extracutaneous manifestation that can lead to progressive joint damage and functional disability if not recognized early.
Methotrexate remains a commonly used systemic therapy in both chronic plaque psoriasis and psoriatic arthritis, mainly through anti-inflammatory and immunomodulatory effects.
CAPN12 is a calcium-dependent cysteine protease expressed in the epidermis and hair follicles and implicated in skin barrier biology and keratinocyte differentiation. Recent integrative single-cell RNA sequencing and Mendelian randomization work identified CAPN12 among genetically informed psoriasis related candidate genes and linked it to increased psoriasis susceptibility.
The same work reported that these candidate genes were predominantly expressed in CD4+ T cells, supporting the feasibility of peripheral blood mononuclear cell-based expression assessment .
Because methotrexate can modulate immune-cell activity, this study will restrict patient recruitment to methotrexate-treated patients on a stable regimen. This design aims to explore whether CAPN12 expression can discriminate between methotrexate-treated cutaneous-only psoriasis and methotrexate-treated psoriatic arthritis, and whether CAPN12 expression correlates with clinical activity indices.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Sherine Adly Hashem, MSc
- Telefonnummer: +201011000258
- E-post: Sherry.adly.7@gmail.com
Studera Kontakt Backup
- Namn: Soheir Abdel Hamid Ali, M.D
- Telefonnummer: +201066877345
- E-post: Soher.abdelhamed@med.svu.edu.eg
Studieorter
-
-
-
Qina, Egypten
- Rekrytering
- South Valley University Hospital
-
Kontakt:
- Mohamed Hosney Hassan, Professor
- Telefonnummer: +201006393764
- E-post: mohammedhosneyhassan@med.svu.edu.eg
-
Kontakt:
- Amr Mohamed Alnoby Aldowy, Lecturer
- Telefonnummer: +201017789975
- E-post: Amrnoby1990@gmail.com
-
Underutredare:
- Shimaa Saber Ahmed, M.D
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
- Type of the study: Case-control molecular study.
- Study Setting: Qena University Hospital, Department of Dermatology, Venereology& Andrology and Rheumatology Clinics.
- Study subjects: This study will include adult participants recruited from the outpatient Dermatology and Rheumatology Clinics.
- Receiver operating characteristic curve analysis will be used to evaluate the diagnostic performance of CAPN12 expression.
- Multivariate logistic regression may be performed to test whether CAPN12 expression is independently associated with psoriatic arthritis status.
Beskrivning
Inclusion Criteria:
- Patients aged 18 -70 years.
- The severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI > 12 (severe severity).
- Confirmed diagnosis: Psoriasis vulgaris (PsV) or Psoriatic arthritis (PsA) diagnosed by a dermatologist/rheumatologist.
- Willingness to participate: Signed informed consent.
- Patients on stable dose of methotrexate (MTX) therapy.
- Availability for follow-up: Patients must be willing and able to attend scheduled visit.
Exclusion Criteria:
- Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).
- Pregnancy and lactation.
- Patients currently undergoing immunosuppressive or systemic therapies.
- Patients with known genetic disorders affect immune system function.
- Patients with liver or kidney impairment.
- Patients with allergy or contraindication to methotrexate.
- Patients with active or uncontrolled infections, including chronic infections like tuberculosis.
- Previous genetic analysis: Patients who have previously undergone genetic analysis for the CAPN12 gene expression.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: CASE_CONTROL
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Chronic plaque psoriasis group
About 35 patients suffering from chronic plaque psoriasis and clinically diagnosed chronic plaque psoriasis receiving a stable methotrexate regimen for at least 12 weeks, with no clinical evidence of psoriatic arthritis.The recommended starting dose for a patient with no risk factors is 10 to 20 mg/wk, the therapeutic dose for most patients is 15 mg/wk, and the maximum dose is between 20 - 25 mg/wk. |
to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.
Andra namn:
|
|
Psoriatic arthritis group
About 35 patients suffering from Psoriatic arthritis and diagnosed with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR) and receiving a stable methotrexate regimen for at least 12 weeks.The recommended starting dose for a patient with no risk factors is 10 to 20 mg/wk, the therapeutic dose for most patients is 15 mg/wk, and the maximum dose is between 20 - 25 mg/wk. |
to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.
Andra namn:
|
|
Healthy Control group
About 35 participants inwhich age- and sex-matched apparently healthy individuals with no history of psoriasis, psoriatic arthritis, other autoimmune or chronic inflammatory diseases, and no history of methotrexate therapy. |
to evaluate CAPN12 gene expression as a potential molecular discriminator between methotrexate-treated chronic plaque psoriasis patients and methotrexate treated psoriatic arthritis patients.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
CAPN12 mRNA expression
Tidsram: 3 Months
|
Assessment of the Difference in relative CAPN12 mRNA expression among the three studied groups. |
3 Months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Pain Relief
Tidsram: 3 Months
|
Assessment of the patients of the study from the pain after treatment using Visual Analogue Scale (VAS) where as 0 for none up to 10 for very severe |
3 Months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Eisa Mohammed Hegazy, M.D, Professor of Dermatology,Venereology and Andrology,Faculty of Medicine
- Studierektor: Marwa Alyan Abdelaziz Mohammed, M.D, Lecturer of Dermatology,Venereology and Andrology,Faculty of Medicine
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Skelettsjukdomar
- Muskuloskeletala sjukdomar
- Artrit
- Ledsjukdomar
- Spinal sjukdomar
- Spondylarthropatier
- Hudsjukdomar, Papulosquamous
- Hudsjukdomar
- Spondylartrit
- Spondylit
- Psoriasis
- Hud- och bindvävssjukdomar
- Artrit, psoriasis
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Pteriner
- Pteridiner
- Aminopterin
- Metotrexat
Andra studie-ID-nummer
- CAPN12 Gene Expression
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .